bioAffinity Technologies, Inc. — Earnings Release 2024

Jul 9, 2024

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

July 9, 2024

Date of Report (Date of earliest event reported)

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-41463	46-5211056
(State
or other jurisdiction of
incorporation)	(Commission File
Number)	(I.R.S.
Employer Identification
Number)

22211 W Interstate 10

Suite 1206

San Antonio , Texas 78257

(210) 698-5334

(Address of principal executive offices and Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Common
Stock, par value $0.007 per share | BIAF | The Nasdaq Stock Market LLC |
| Tradeable
Warrants to purchase Common Stock | BIAFW | The Nasdaq Stock Market LLC |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 2.02. Results of Operations and Financial Condition.

On July 9, 2024, bioAffinity Technologies, Inc. (the “Company”) issued a press release that included financial information for its fiscal quarter ended June 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 8.01. Other Events

On July 9, 2024, the Company issued a press release that included financial information for its fiscal quarter ended June 30, 2024, which included a reported 217% growth in second-quarter sales over first quarter 2024 and 53 CyPath® Lung tests ordered by physicians in the first quarter of 2024 compared to 168 CyPath® Lung tests ordered by physicians in the second quarter of 2024 .

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished with this Current Report on Form 8-K:

Exhibit	Description
99.1	Press Release issued by bioAffinity Technologies, Inc. dated July 9, 2024
104	Cover
Page Interactive Data File (embedded within the Inline XBRL document)

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| bioAffinity
Technologies, Inc. | |
| --- | --- |
| By: | /s/
Maria Zannes |
| | Maria
Zannes |
| | President
and Chief Executive Officer |

Dated: July 9, 2024

Field: Page; Sequence: 3; Options: Last

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJx1kdFOwkAQRb+Af5g0PhLYVg3YN22QGME00KCvQztIQ7vTzG4RPsm/dNsC8qCbTTaTO+femazn9b0pP+cFCXw8LWaQUFkVaAkWtCEhnZLriF5eQ3Dvgj5zYwW1bcszGLFjyDH3g+AWndC27nNDWQhqNFTjYXAHahyqB4jnXq/RI9abPCNtcywAdQaxcCU5WZRj55DggTWXxzZqRWJy1iH4A9XJ3xAoP4A33uMXy87AbBZ5vX57et5UuK5c1+RgSTckTAoqXZzp6N/bTpPWxnIZJoIZ4bqgd5RmS5NwXEu6RUNux5L10nK6m1O5JnGUr4LAV4+ngS4wnGmwDNWJh84AWoc/oq/8Y5QVFjWpgVKjmGS5RaF/Qq9d+1ChwL5B4aaFoXK/Yxr8nPgDA/+WLQ==